BCAB RSI Chart
Last 7 days
4.4%
Last 30 days
11.9%
Last 90 days
25.2%
Trailing 12 Months
-13.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2021 | 0 | 590.0K | 400.0K | 250.0K |
2020 | 4.0M | 2.8M | 1.6M | 429.0K |
2019 | 0 | 0 | 0 | 5.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 30, 2024 | sievers eric | sold (taxes) | -1,292 | 2.26 | -572 | chief medical officer |
Apr 30, 2024 | smith scott andrew | sold (taxes) | -4,929 | 2.26 | -2,181 | - |
Mar 31, 2024 | smith scott andrew | sold (taxes) | -7,502 | 3.44 | -2,181 | - |
Mar 31, 2024 | sievers eric | sold (taxes) | -1,967 | 3.44 | -572 | chief medical officer |
Feb 29, 2024 | smith scott andrew | sold (taxes) | -5,888 | 2.7 | -2,181 | - |
Feb 29, 2024 | sievers eric | sold (taxes) | -1,544 | 2.7 | -572 | chief medical officer |
Feb 16, 2024 | short jay m phd | acquired | - | - | 417,000 | chief executive officer |
Feb 15, 2024 | sievers eric | acquired | - | - | 122,000 | chief medical officer |
Which funds bought or sold BCAB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Tidal Investments LLC | reduced | -5.88 | 122,857 | 502,302 | 0.01% |
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -287,818 | - | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.91 | -2,611 | 15,298 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -0.69 | 69,934 | 249,871 | -% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | sold off | -100 | -1,476,000 | - | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -89.26 | -28,000 | 4,000 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | added | 21.76 | 66,986 | 162,313 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | added | 18.85 | 278,281 | 698,626 | -% |
May 15, 2024 | PERCEPTIVE ADVISORS LLC | sold off | -100 | -179,580 | - | -% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | reduced | -41.6 | -1,138,410 | 5,070,820 | 0.53% |
Unveiling BioAtla, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to BioAtla, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
BioAtla, Inc. News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Revenue | - | - | - | 250 | - | 150 | 190 | - | - |
Operating Expenses | -0.9% | 23,488 | 23,695 | 30,710 | 16,455 | 8,165 | 4,710 | 1,198 | - |
S&GA Expenses | -1.4% | 7,040 | 7,142 | 15,860 | 5,507 | 3,301 | 1,787 | 463 | - |
R&D Expenses | -0.6% | 16,448 | 16,553 | 14,850 | 10,485 | 4,864 | 2,923 | 1,661 | - |
Interest Expenses | - | - | - | 1.00 | 2.00 | 86.00 | 754 | 547 | - |
Net Income | -2.0% | -23,390 | -22,930 | -30,381 | -16,395 | -11,632 | -6,222 | -1,604 | - |
Net Income Margin | -72.7% | -381.61* | -221.02* | -130.69* | -83.57* | -18.41* | -10.61* | -7.45* | -5.74* |
Free Cashflow | -64.6% | -20,949 | -12,726 | -13,545 | -14,006 | -15,462 | -3,052 | -3,814 | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -25.5% | 89.00 | 120 | 151 | 180 | 205 | 226 | 189 | 213 | 231 | 254 | 278 | 217 | 229 | 245 |
Current Assets | -25.8% | 86.00 | 116 | 148 | 175 | 200 | 220 | 183 | 207 | 224 | 247 | 274 | 212 | 225 | 241 |
Cash Equivalents | -27.7% | 81.00 | 111 | 141 | 169 | 193 | 216 | 178 | 202 | 219 | 245 | 270 | 208 | 221 | 239 |
Net PPE | -15.0% | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
Liabilities | -19.4% | 39.00 | 49.00 | 57.00 | 55.00 | 48.00 | 45.00 | 46.00 | 49.00 | 41.00 | 44.00 | 47.00 | 39.00 | 33.00 | 35.00 |
Current Liabilities | -32.0% | 19.00 | 28.00 | 36.00 | 34.00 | 26.00 | 23.00 | 24.00 | 26.00 | 17.00 | 20.00 | 45.00 | 36.00 | 31.00 | 32.00 |
Shareholder's Equity | -29.7% | 50.00 | 71.00 | 95.00 | 125 | 156 | 180 | 143 | 165 | 190 | 211 | 231 | 178 | 196 | 210 |
Retained Earnings | -5.6% | -439 | -416 | -389 | -356 | -320 | -292 | -265 | -239 | -210 | -186 | -162 | -140 | -109 | -90.92 |
Additional Paid-In Capital | 0.5% | 489 | 487 | 484 | 481 | 477 | 473 | 408 | 404 | 401 | 397 | 394 | 318 | 306 | 301 |
Shares Outstanding | 0.1% | 48.00 | 48.00 | 48.00 | 48.00 | 48.00 | 46.00 | 38.00 | 36.00 | 37.00 | 36.00 | 34.00 | 34.00 | 34.00 | 32.00 |
Float | - | - | - | - | 91.00 | - | - | - | 69.00 | - | - | - | 1,000 | - | - |
Cashflow (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | -3.0% | -30,828 | -29,922 | -27,345 | -24,094 | -22,654 | -24,347 | -24,016 | -16,921 | -25,136 | -20,949 | -12,726 | -13,545 | -14,994 | -14,006 | -15,462 | -3,052 | -3,814 | - |
Share Based Compensation | -16.0% | 2,300 | 2,738 | 3,517 | 3,675 | 3,614 | 3,501 | 3,588 | 3,842 | 3,632 | 3,810 | 4,366 | 12,298 | 4,643 | 3,022 | - | - | - | - |
Cashflow From Investing | 100.0% | - | -8.00 | -25.00 | -15.00 | -50.00 | -31.00 | -58.00 | -166 | -10.00 | -89.00 | -99.00 | -235 | -501 | -395 | -109 | -66.00 | -20.00 | - |
Cashflow From Financing | -110.9% | -13.00 | 119 | -41.00 | 115 | -116 | 61,765 | -96.00 | -51.00 | -405 | -3,908 | 75,141 | 190 | -1,911 | 196,249 | 72,144 | 2,932 | 500 | - |
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development expense | $ 18,852 | $ 21,697 |
General and administrative expense | 5,605 | 7,233 |
Total operating expenses | 24,457 | 28,930 |
Loss from operations | (24,457) | (28,930) |
Other income: | ||
Interest income | 1,223 | 1,480 |
Other income | 0 | (10) |
Total other income | 1,223 | 1,470 |
Net loss and comprehensive loss | $ (23,234) | $ (27,460) |
Net loss per common share, basic | $ (0.48) | $ (0.58) |
Net loss per common share, diluted | $ (0.48) | $ (0.58) |
Weighted-average shares of common stock outstanding, basic | 48,087,460 | 47,578,418 |
Weighted-average shares of common stock outstanding, diluted | 48,087,460 | 47,578,418 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 80,630 | $ 111,471 |
Prepaid expenses and other current assets | 5,795 | 4,935 |
Total current assets | 86,425 | 116,406 |
Property and equipment, net | 1,363 | 1,603 |
Operating lease right-of-use asset, net | 1,255 | 1,495 |
Other assets | 154 | 154 |
Total assets | 89,197 | 119,658 |
Current liabilities: | ||
Accounts payable and accrued expenses | 17,751 | 26,720 |
Operating lease liabilities | 1,509 | 1,624 |
Total current liabilities | 19,260 | 28,344 |
Operating lease liabilities, less current portion | 415 | 836 |
Liability to licensor | 19,806 | 19,806 |
Total liabilities | 39,481 | 48,986 |
Commitments and contingencies (Note 5) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock value | 5 | 5 |
Additional paid-in capital | 489,208 | 486,930 |
Accumulated deficit | (439,497) | (416,263) |
Total stockholders’ equity | 49,716 | 70,672 |
Total liabilities and stockholders’ equity | $ 89,197 | $ 119,658 |